Fosamax Exposure Linked to Osteonecrosis of the Jaw: Mechanisms and Evidence

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Advisories to Targeted Risk Assessment

The legacy of mass production in the health and science information domain has long emphasized broad public awareness of general wellness and disease prevention. This heritage includes disseminating foundational knowledge about medication safety and potential adverse effects, often framed within a universal, patient-oriented context. For instance, historical communications have highlighted the importance of understanding drug interactions and reporting side effects, yet these messages typically remained at a population level, without delving into specific occupational or environmental exposure pathways. As the focus shifts from general health advisories to more targeted risk assessments, a natural pivot emerges toward examining how certain pharmaceutical exposures may pose distinct hazards in specific settings. The transition from a broad public health lens to an occupational exposure concern requires acknowledging that individuals in manufacturing, healthcare, or related industries may encounter higher or more sustained contact with active pharmaceutical ingredients. This shift does not involve mechanistic claims about disease causation but rather reframes the discussion around the potential for differential exposure levels in the workplace. Thus, the legacy of general health information provides a foundation for now considering how occupational contexts might alter risk profiles. The concern moves from a universal patient warning to a focused inquiry into whether workers handling specific compounds, such as those involved in bisphosphonate production, face unique exposure scenarios that warrant separate evaluation. This transition maintains academic neutrality by simply redirecting attention to the workplace as a variable in exposure assessment, without asserting any specific health outcomes.

Bridging to Fosamax and Osteonecrosis of the Jaw

Building on the recognition that occupational or sustained exposure to active pharmaceutical ingredients may alter risk profiles, we now turn to a specific medication: Fosamax (alendronate). Fosamax is a bisphosphonate approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its use has been associated with a serious adverse effect known as osteonecrosis of the jaw (ONJ), a condition characterized by exposed, non-healing bone in the maxillofacial region. Clinical presentation and diagnosis of ONJ typically involve the presence of exposed bone in the jaw that persists for more than eight weeks, often accompanied by pain, swelling, infection, or delayed healing after dental procedures. The condition can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Diagnosis is primarily clinical, based on visual examination and patient history, and may be supported by imaging studies to rule out other causes.

Mechanistic Pathways Linking Fosamax to ONJ

The mechanistic pathways linking Fosamax to ONJ involve the drug's pharmacological action as a bisphosphonate. Bisphosphonates like alendronate inhibit osteoclast-mediated bone resorption, which reduces bone turnover. In the jawbone, this suppression of remodeling may impair the normal healing response to microdamage or dental procedures. Multiscale characterization of jawbone treated with osteoporosis therapeutic agents has provided information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077). Studies in estrogen-deficient rats have examined the effects of bisphosphonate (alendronate) on jawbone properties, including tissue mineral density distribution and mechanical stability of teeth in the alveolar socket (https://pubmed.ncbi.nlm.nih.gov/40345077). These findings suggest that bisphosphonate treatment alters the structural and mechanical characteristics of jawbone, potentially increasing susceptibility to ONJ.

Risk Factors and Clinical Considerations

Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Regarding the adequacy of warnings, the prescribing information for Fosamax includes a specific section on osteonecrosis of the jaw under Warnings and Precautions. The label states that ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). It also notes that the time to onset of symptoms varied from one day to several months after starting the drug, and that most patients had relief of symptoms after stopping (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). A subset of patients had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Causation and Temporal Relationship

Causation-related considerations for affected patients involve establishing a temporal relationship between Fosamax exposure and the development of ONJ. The timeline between exposure and documented harm can vary, with symptom onset ranging from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, ONJ may also occur after longer periods of use, and the risk increases with duration of bisphosphonate exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients who develop ONJ, discontinuation of Fosamax may lead to symptom relief, though a subset may experience recurrence upon rechallenge (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The presence of other risk factors, such as dental procedures or comorbidities, should be considered when assessing causation. In summary, the evidence supports a link between Fosamax exposure and osteonecrosis of the jaw, with mechanistic plausibility based on bisphosphonate pharmacology and jawbone-specific effects. Warnings in the prescribing information address this risk, and the timeline for symptom onset can range from days to months after starting therapy. Patients and healthcare providers should be aware of risk factors and consider discontinuation of bisphosphonate treatment prior to invasive dental procedures to reduce the risk of ONJ.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Fosamax and what is it used for?

Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

How does Fosamax cause osteonecrosis of the jaw?

Fosamax inhibits osteoclast-mediated bone resorption, reducing bone turnover. In the jawbone, this suppression of remodeling may impair healing after microdamage or dental procedures, leading to ONJ. Studies have shown that bisphosphonate treatment alters jawbone structure and mechanical properties, increasing susceptibility (https://pubmed.ncbi.nlm.nih.gov/40345077).

What are the risk factors for developing ONJ while taking Fosamax?

Risk factors include invasive dental procedures, cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and comorbidities like periodontal disease. The risk increases with longer duration of bisphosphonate exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.